Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
PMID: 19734799
2009
Journal of acquired immune deficiency syndromes (1999)
Method: L100I, K101E/P, K103N/S, V106A/M, Y181C/I/V, V179F, Y188C/H/L, G190A/S/E/Q and M230L were defined as major NNRTI resistance mutations.
Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India.
Discussion: V106M was predominant over V106A, as reported previously, for subtype C viruses because the natural GTG polymorphism at codon 106 in clade C variants is distinct from clade B viruses.
Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.
PMID: 18582198
2008
The Journal of infectious diseases
Table: V106A
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
PMID: 18665583
2008
Journal of medicinal chemistry
Abstract: Structures of mutant RTs (K103N, V106A/Y181C) with benzophenones showed only small rearrangements of the NNRTIs relative to wild-type.
Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
PMID: 18684096
2008
The Journal of infectious diseases
Table: V106A
Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan.
Abstract: Twenty-three cases, including three recently infected patients, were infected with HIV-1 having major drug-resistance mutations, including M41L, D67N, L100I, K103N, V106A, M184I, M184V, L210W, and revertant mutations at the 215 codon in reverse transcriptase and M46I in protease encoding regions.
Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients.
Abstract: RESULTS: Direct sequencing of DNA provirus disclosed key mutations (such as G190A/S, V106A, K103N and T215F) to RT inhibitors more frequently (7 patients out 31) than in plasma RNA (2 out of 31).
HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
Method: NNRTI-selected mutations included A98G, L100I, K101E/P/N/H, K103N/S, V106A/M, V108I, V179D/E, Y181C/I/V, Y188L/C/H, G190A/S/E/Q, P225H, F227L, M230L, P236L, and K238T.
In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Abstract: Interestingly, HIV-1 variants constructed to contain the T215Y zidovudine (AZT)-resistance associated substitution with CPV-resistance associated substitutions V106A, Y181C, F227C, F227L, L234I or V106A/F227L demonstrated 2.4-5.4-fold increased susceptibility to CPV.
Abstract: Results demonstrate that HIV-1 variants selected at increasing CPV concentrations contained multiple substitutions in diverse patterns including L100I, Y181C, G190E and/or L234I in various combinations with K101R/E, K10
Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.
HIV mutation literature information.
PMID: 
2009
Journal of acquired immune deficiency syndromes (1999)
Browser Board
Co-occurred Entities
Filtrator
ViMRT